【摘要】 目的本文旨在进一步探究干扰素α(IFN-α)治疗慢性病毒性肝炎中对肝纤维化的疗效,证实IFN-α的抗纤维化作用;同时从分子水平来探讨阻止肝纤维化进展的机理,为临床防治肝纤维化提供理论依据。方法采用ELISA技术测定20例慢性病毒性肝炎患者IFN-α治疗前后Ⅲ型前胶原(PⅢP)、Ⅳ型胶原(CⅣ)、层粘蛋白(LN)、透明质酸(HA)及血小板衍生生长因子-BB(PDGF-BB)含量。结果实验组20例慢性病毒性肝炎患者经IFN-α治疗后,其血清CⅣ、HA、LN、PDGF-BB含量下降非常显著(P<0.01),血清PⅢP含量亦明显下降(P<0.05)。患者组随着肝病严重程度的加重血清PDGF-BB水平亦随之上升,且血清PDGF-BB水平与PⅢP、CⅣ、LN水平呈正相关。结论IFN-α治疗慢性病毒性肝炎肝纤维化的有效性是肯定的。慢性病毒性肝炎患者血清PDGF-BB水平升高,且其升高与肝纤维化有良好的相关性,可作为观察抗肝纤维化药物疗效的指标。IFN-α抑制PDGF-BB的表达可能是其抗纤维化作用的重要机制之一。更多还原

【Abstract】 Objective To investigate the effects of Interferon alpha (IFN-α) on patients with chronic viral hepatitis in the anti-fibrosis course, and to try to survey its molecular mechanism in treatment and prevention of hepatic fibrosis. And provide a theoretical basis for its therapy. Methods We studied 20 patients with liver fibrosis caused by chronic viral hepatitis who were treated with IFN-α. Enzyme linked Immunosorbent Assay(ELISA) were used to quantify the serum levels of PDGF-BB,PⅢP、CⅣ、LN、HA before and after the therapy. Results After the treatment, the serum levels of CⅣ,HA,LN,PDGF-BB were much less than those before treatment(P<0.01) and the serum levels of PⅢP were less than those before treatment(P<0.05). Furthermore, The serum concentration of PDGF-BB increased according to the severity of the disease and had linear correlation with the serum concentration of PⅢP、CⅣ and LN(P<0.05). Conclusions This study confirms that interferon alpha therapy is very effective for hepatic fibrosis of chronic viral hepatitis. And the observations shows that the serum concentration of PDGF-BB of patients with chronic viral hepatitis increased and the PDGF-BB levels are closely related to hepatic fibrosis. It is suggested that PDGF-BB may be a novel serum diagnostic index for hepatic fibrosis. Furthermore, anti-fibrosis mechanism of IFN-α partly is probably due to its inhibiting the expression of PDGF-BB.更多还原